Oracea, to treat inflammatory lesions on skin due to rosacea/skin conditions


Stony Brook University School of Medicine


Lorne Golub, DMD, MSc, of the Department of Oral Biology and Pathology at Stony Brook Medicine


Rosacea affects an estimated 16 million Americans. Dr. Golub was the principal investigator of the research leading to the development of Oracea. The drug delivers a dose of doxycycline that is not strong enough to kill bacteria, but that will reduce lesions and inflammation.


FDA approval in 2006